Published on : Mar 01, 2017
ALBANY, NY, March 01, 2017: The report is a comprehensive study of several promising pipeline drugs pertaining to immunology that are expected to enter the market in the near future.
The disorders of the immune system can lead to chronic or acute inflammation, which causes pain and hampers mobility. With the growing cases of immune system diseases, the demand for efficient drugs is escalating and the research and development done in this field are starting to lay fruits. The report observes that more than two thousand products are currently being actively developed, focusing primarily on infectious diseases, oncology, and central nervous system disorders. The report notes that 40% of the total immunology pipeline for which molecular target was disclosed, accounting for nearly 529 products, act as first-in-class molecular targets.
In addition to that, it has been seen that products that are being developed for this therapy area has a high degree crossover between immunology indications in terms of their underlying pathophysiology. This additional benefit is further fueling the investments in the large therapy immunology pipeline market. The report evaluates that nearly one-fifth of first-in-class pipeline products are intentionally developed for two or more indications, helping the investors and companies to reach a larger pool of patients. Via a proprietary matrix, the report access the therapeutic potential of first-in-class targets and ranks the according to clinical trial potential and most promising early-stage targets.
Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=970728
The report estimates the implications of overlap in the pathophysiology of immune diseases, studies the current standard of treatment across the verticals of this market, points out essential lessons to be learned from the companies that are currently innovating and building these products, highlights the most promising molecule types and molecule targets within the pipeline, and presents a ranking of the most promising first-in-class targets. Besides identifying the leading product and companies along with unmet geographical demands in this market, the report also reviews essential pipeline trends by analyzing therapies by molecular type and target and by stage of development.
In the section on immunology signaling network, disease causation, and innovation alignment, the report studies signaling pathways and first-in-class molecular target integration, the complexity of signaling networks, and first-in-class matrix assessment. The chapter on strategic consolidations analyzes licensing deals and co-development deals by region including year and valuation, stage of development, molecular type, and molecular target. Some of the first-in-class target and pipeline program evaluated in the report are related to Toll-Like Receptors 3, 6 and 8, Spleen Tyrosine Kinase, IL-7R, C-C Chemokine Receptor Type 6, P2RX7, ITK, IRAK4, Orai1, and Tumor Necrosis Factor Receptor Superfamily Member 5.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org